Zylexa Pharma Ltd
Registered number: 08027678
Balance Sheet
as at 31 March 2025
Notes 2025 2024
£ £
Fixed assets
Tangible assets 3 1,104 -
Investments 4 10,500 10,500
11,604 10,500
Current assets
Debtors 5 28,325 19,254
Cash at bank and in hand 2,205 9,404
30,530 28,658
Creditors: amounts falling due within one year 6 (24,353) (12,525)
Net current assets 6,177 16,133
Total assets less current liabilities 17,781 26,633
Creditors: amounts falling due after more than one year 7 (13,333) (23,333)
Net assets 4,448 3,300
Capital and reserves
Called up share capital 100 100
Profit and loss account 4,348 3,200
Shareholder's funds 4,448 3,300
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The member has not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Hamna Ismailjee
Director
Approved by the board on 20 August 2025
Zylexa Pharma Ltd
Notes to the Accounts
for the year ended 31 March 2025
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery over 4 years
Fixtures and fittings over 4 years
Investments
Investments in unquoted equity instruments are measured at fair value. Changes in fair value are recognised in profit or loss. Fair value is estimated by using a valuation technique.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2025 2024
Number Number
Average number of persons employed by the company 1 1
3 Tangible fixed assets
Plant & Machinery Fixtures & Fittings Total
£ £ £
Cost
At 1 April 2024 2,311 6,062 8,373
Additions 1,104 - 1,104
At 31 March 2025 3,415 6,062 9,477
Depreciation
At 1 April 2024 2,311 6,062 8,373
At 31 March 2025 2,311 6,062 8,373
Net book value
At 31 March 2025 1,104 - 1,104
4 Investments
Unlisted
investments
£
Cost
At 1 April 2024 10,500
At 31 March 2025 10,500
5 Debtors 2025 2024
£ £
Trade debtors 14,616 13,373
Other debtors 13,709 5,881
28,325 19,254
6 Creditors: amounts falling due within one year 2025 2024
£ £
Other loans < 1 year 18,571 4,674
Trade creditors 7,736 7,736
Other taxes and social security costs (623) (582)
Accruals 1,550 1,550
Director's account (2,881) (853)
24,353 12,525
7 Creditors: amounts falling due after one year 2025 2024
£ £
Bank loans 13,333 23,333
8 Profit and loss account 2025
£
At 1 April 2024 3,200
Profit for the year 1,148
Dividends -
At 31 March 2025 4,348
9 Dividends 2025 2024
£ £
Dividends for which the company became liable during the year: - -
- -
10 Contingent liabilties
The company is a corporate member of I.F. R&D LLP and is liable to the assets of the LLP in the event of a winding-up before 1st July 2025. The maximum liability in relation to this undertaking is £62,892. The company does not believe that a winding-up of the LLP is probable and has not made provision for the liability at 31 March 2025.
11 Related party transactions
Included within the creditors at the year end is £2,881 (2024: £853) due from Mrs Hamna Ismailjee, the company director. During the period the company paid £8,285 of expenses on behalf of the director and the director introduced £6,257.
12 Controlling party
The ultimate controlling party is the director and sole shareholder Mrs Hamna Ismailjee.
13 Other information
Zylexa Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:
32 Westland Avenue
Bolton
BL1 5NP
Zylexa Pharma Ltd 08027678 false 2024-04-01 2025-03-31 2025-03-31 VT Final Accounts April 2025 Hamna Ismailjee No description of principal activity 08027678 2023-04-01 2024-03-31 08027678 core:WithinOneYear 2024-03-31 08027678 core:AfterOneYear 2024-03-31 08027678 core:ShareCapital 2024-03-31 08027678 core:RetainedEarningsAccumulatedLosses 2024-03-31 08027678 2024-04-01 2025-03-31 08027678 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 08027678 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 08027678 bus:Director40 2024-04-01 2025-03-31 08027678 1 2024-04-01 2025-03-31 08027678 2 2024-04-01 2025-03-31 08027678 core:PlantMachinery 2024-04-01 2025-03-31 08027678 core:Vehicles 2024-04-01 2025-03-31 08027678 countries:England 2024-04-01 2025-03-31 08027678 bus:FRS102 2024-04-01 2025-03-31 08027678 bus:FilletedAccounts 2024-04-01 2025-03-31 08027678 2025-03-31 08027678 core:WithinOneYear 2025-03-31 08027678 core:AfterOneYear 2025-03-31 08027678 core:ShareCapital 2025-03-31 08027678 core:RetainedEarningsAccumulatedLosses 2025-03-31 08027678 core:PlantMachinery 2025-03-31 08027678 core:Vehicles 2025-03-31 08027678 2024-03-31 08027678 core:PlantMachinery 2024-03-31 08027678 core:Vehicles 2024-03-31 iso4217:GBP xbrli:pure